InMed Pharmaceuticals Inc. INM 0.21 InMed Pharmaceuticals Inc.

Home
⇒ 
Stock List ⇒ InMed Pharmaceuticals Inc.
Range:0.121-2.08Vol Avg:6941903Last Div:0Changes:-0.02
Beta:0.74Cap:0.00BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Mon May 05 2014Empoloyees:13
CUSIP:457637601CIK:0001728328ISIN:CA4576376012Country:CA
CEO:Mr. Eric A. Adams B.S. Chem., M.I.B.Website:https://www.inmedpharma.com
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow